Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Cynosure Group LLC

Cynosure Group LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 189.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,786 shares of the medical research company’s stock after acquiring an additional 3,131 shares during the period. Cynosure Group LLC’s holdings in Thermo Fisher Scientific were worth $2,490,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Bryce Point Capital LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $1,536,000. Huntington National Bank boosted its holdings in Thermo Fisher Scientific by 1.1% during the fourth quarter. Huntington National Bank now owns 133,780 shares of the medical research company’s stock worth $69,596,000 after buying an additional 1,405 shares in the last quarter. RFG Bristol Wealth Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $1,729,000. Potomac Fund Management Inc. ADV acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $224,000. Finally, May Hill Capital LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter worth about $227,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,900 shares of company stock worth $13,106,062. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 3.0 %

TMO stock opened at $482.51 on Wednesday. The company’s 50 day moving average price is $538.56 and its 200 day moving average price is $550.11. The firm has a market capitalization of $182.03 billion, a price-to-earnings ratio of 29.19, a PEG ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a fifty-two week low of $481.21 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.36%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on TMO shares. Wells Fargo & Company boosted their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Raymond James reiterated an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Royal Bank of Canada set a $693.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 31st. Citigroup cut their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.